April 23, 2025 03:35 PM EDTUpdated 04:19 PM

Large vaccine makers stand by their investments despite US headwinds

Max Bayer

Pharma Reporter

WASHINGTON — Representatives from large vaccine makers say they are committed to their pipelines, despite a new wave of scrutiny in the US that risks diminishing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Large vaccine makers stand by their investments despite US headwinds

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

Pharma's wins and losses in Trump's sprawling executive order on drug prices

China’s biotech market is staging a comeback that US biotech can only wish for

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Large vac­cine mak­ers stand by their in­vest­ments de­spite US head­winds

Pharma Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Large vaccine makers stand by their investments despite US headwinds